Tag Archives: Madrigal Pharmaceuticals

Ypsomed Launches Remote Bolus Feature; Lannett Completes Bs-glargine Pivotal Trial; Madrigal Initiates MAESTRO-NASH Outcomes Study for Resmetirom

Three cardiometabolic-related news items have been observed: Ypsomed announced the launch of a smartphone bolus delivery feature for its mylife YpsoPump using the mylife App; Lannett announced it completed subject dosing in its Ph1 bs-glargine pivotal trial (view CT.gov record); and Madrigal announced the initiation of a Ph3 MAESTRO-NASH Outcomes study evaluating the effect of QD oral 80mg resmetirom compared to placebo in patients with compensated NASH cirrhosis (view CT.gov record). Below, FENIX provides context and insight on the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Pfizer and Ionis Discontinue Vupanorsen in Dyslipidemia; Glooko Acquires xbird; Madrigal Announces Positive Ph3 MAESTRO-NAFLD-1 Topline Results

Three cardiometabolic-related news items have been observed: Pfizer and Ionis announced they are discontinuing vupanorsen development for dyslipidemia following Ph2b topline results; Glooko announced it has acquired xbird; and Madrigal Pharmaceuticals announced positive topline results from its Ph3 MAESTRO-NAFLD-1 resmetirom study and hosted an associated webcast (listen to webcast here; slides). Below, FENIX provides highlights and insights for the respective new items.

This content is for Read Less members only.

Already a member? Log in here